<DOC>
	<DOC>NCT02070835</DOC>
	<brief_summary>Diabetic foot ulcer is one of the refractory wounds and always poses many challenges in clinical practice. This study was conducted to have a prospective, randomised, controlled study compare the safety and efficacy of the ReCell® technology with skin graft (experiment group) with split-thickness skin graft (STSG, control group) alone on treating diabetic foot ulcers.</brief_summary>
	<brief_title>Study of ReCell® Treating for Diabetic Foot Ulcers</brief_title>
	<detailed_description>The primary objective of this study is to assess the effectiveness and safety of ReCell® with skin graft (experiment group) vs. skin graft (control group) for the treatment of non-healing diabetic foot ulcers. Our hypothesis is that the methods of experiment group is better than the control group.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Patients aged over 18 years old with a diagnosis of type 1 or type 2 diabetes who had a diabetic low extremity ulcer last for over 4 weeks with a stage 2 by Wagner's scale size more than 3 cm2 absence of vascular reconstruction (ankle brachial indices between 0.7 and 1.2) had indications of skin grafting were eligible for inclusion patients with medical conditions that would impair wound healing (e.g. malignancy, autoimmune disease), using corticosteroids or immunosuppressor a high anesthesiology or surgical risk uncontrolled hyperglycemia (preoperative HbA1c greater than 12.0%)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>ReCell</keyword>
</DOC>